To investigate whether interference with RARRES2-mediated lipid metabolic reprogramming affects the malignant phenotype of breast cancer cells, we conducted experiments using etomoxir, a CPT1 inhibitor, on MDA-MB-231 cell line with altered RARRES2 expression. Here, CPT1A is linked to breast carcinoma.